2022 Fiscal Year Final Research Report

The NEFH pathway may be a novel therapeutic target for ovarian clear cell carcinoma

Research Project

PDF

Project/Area Number	19K09759
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 56040:Obstetrics and gynecology-related
Research Institution	Iwate Medical University
Principal Investigator	ITAMOCHI Hiroaki 岩手医科大学, 医学部, 教授 (20314601)
Co-Investigator(Kenkyū-buntansha)	庄子忠宏岩手医科大学, 医学部, 特任准教授 (00337148) 永沢崇幸岩手医科大学, 医学部, 助教 (10453309) 苫米地英俊岩手医科大学, 医学部, 助教 (10771363) 利部正裕岩手医科大学, 医学部, 講師 (30382609) 佐藤誠也岩手医科大学, 医学部, 助教 (30621007) 深川安寿子岩手医科大学, 医学部, 任期付助教 (30772511) 馬場長岩手医科大学, 医学部, 教授 (60508240) 小島淳美岩手医科大学, 医学部, 講師 (60508753)
Project Period (FY)	2019-04-01 – 2023-03-31
Keywords	卵巣明細胞癌 / NEFH / バイオマーカー
Outline of Final Research Achievements	We examined the incidence of NEFH gene mutations in ovarian clear cell carcinoma (OCCC) tissues and their correlation with clinical parameters. The mutations of NEFH gene were found in 49% (27/55) of OCCC. NEFH mutations were not associated with patient age, FIGO stage, PI3k or Akt gene mutations, or PI3K/Akt pathway protein expression levels. The 5-year overall survival rate for patients with NEFH mutations was lower than that for those without mutations (47% vs. 70%). The 5-year overall survival rate for FIGO stage I or II OCCC patients with NEFH mutations was significantly lower than that for those without mutations (64% vs. 94%). Multivariate analysis revealed that NEFH mutation was an independent prognostic factor for FIGO stage I or II OCCC patients. NEFH gene mutation is a promising biomarker that is predictive of patient outcomes and a potential target for OCCC.
Free Research Field	婦人科腫瘍学
Academic Significance and Societal Importance of the Research Achievements	卵巣明細胞癌において、腫瘍組織中のNEFH遺伝子変異は有望な予後予測マ－カ－となり得ることが示唆された。したがって、抗がん剤に抵抗性で予後不良な卵巣癌の一つである明細胞癌において、NEFHは重要なバイオマーカーであり、NEFH経路を標的とした新規治療戦略による予後改善が期待される。